Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120239 | 0.90 | GPR119 (0.38) | GPR119PIK3CDDGAT1FAAHGABRG2 | |
| SCHEMBL20120237 | 0.90 | GPR119 (0.38) | GPR119PIK3CDDGAT1FAAHGABRG2 | |
| SCHEMBL29547275 | 0.90 | GPR119 (0.38) | GPR119PIK3CDDGAT1FAAHGABRG2 | |
| SCHEMBL31411068 | 0.90 | GPR119 (0.38) | GPR119PIK3CDDGAT1FAAHGABRG2 | |
| SCHEMBL20120545 | 0.87 | GPR119 (0.41) | GPR119PIK3CDFAAHGABRG2GABRB3 | |
| SCHEMBL20120542 | 0.87 | GPR119 (0.41) | GPR119PIK3CDFAAHGABRG2GABRB3 | |
| SCHEMBL29548104 | 0.87 | GPR119 (0.41) | GPR119PIK3CDFAAHGABRG2GABRB3 | |
| SCHEMBL20133113 | 0.83 | GPR119 (0.50) | GPR119PIK3CD | |
| SCHEMBL20129203 | 0.83 | NR1H2 (0.41) | GPR119PIK3CDDGAT1GABRG2GABRB3 | |
| SCHEMBL18012185 | 0.82 | GABRG2 (0.41) | GPR119GABRG2GABRB3GABRA5BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | GPR119 3741/4885PIK3CD 2652/4885HRH3 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.